Articles
-
1 week ago |
benzinga.com | Vandana Singh
US President Donald Trump issued a multi-part executive order on Tuesday to lower drug prices and reduce Medicare costs. Within 60 days, the Secretary of Health and Human Services is instructed to seek guidance for the Medicare Drug Price Negotiation Program for initial price applicability year 2028 and how drugmakers should implement the set prices in 2026, 2027, and 2028. This guidance will focus on greater transparency, selecting high-cost drugs, and safeguarding pharmaceutical innovation.
-
1 week ago |
benzinga.com | Vandana Singh
On Tuesday, Bank of America Corp (NYSE:BAC) reported a first-quarter fiscal 2025 net income of $7.4 billion (versus $6.7 billion a year ago) and EPS of $0.90, beating the analyst consensus estimate of $0.81. Revenue increased 6.0% year over year to $27.37 billion, beating the analyst consensus estimate of $26.99 billion, driven by noninterest income growth across all segments and higher net interest income.
Trump Administration Opens Probe Into Foreign Drug Imports, Eyes Tariffs Under National Security Law
1 week ago |
benzinga.com | Vandana Singh
Last week, U.S. President Donald Trump disclosed plans for a “major tariff” on foreign pharmaceuticals. BofA Securities analyst said if the Trump administration plans to impose tariffs on the pharmaceutical industry, it would likely do so through a “Section 232 investigation” under the Trade Expansion Act of 1962 to determine whether importing certain goods threatens national security.
-
1 week ago |
benzinga.com | Vandana Singh
The European Commission (EC) on Tuesday approved Eisai Co., Ltd. ESALY and Biogen Inc.’s BIIB amyloid-beta (Aβ) monoclonal antibody Leqembi (lecanemab),The Commission said it granted the approval under strict conditions. Lecanemab is indicated for adult patients with a clinical diagnosis of mild cognitive impairment (MCI) and mild dementia due to AD (early AD) who are apolipoprotein E ε4 (ApoE ε4) non-carriers or heterozygotes with confirmed amyloid pathology.
-
1 week ago |
benzinga.com | Vandana Singh
Citigroup Inc. C reported on Tuesday that its first-quarter fiscal 2025 revenue growth was 3% year over year and was $21.6 billion, beating the analyst consensus of $21.29 billion. Each of the five interconnected businesses drove this growth. Excluding divestiture-related impacts in both periods, revenues also went up 3%. The firm reported earnings per share of $1.96, increased from $1.58 a year ago, beating the consensus of $1.84.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →